An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

Exclusion Criteria

• •History of other malignancies or concurrent active malignancies within 3 years.
• •Prior treatment with methionine adenosyltransferase 2 alpha (MAT2A) inhibitors (e.g., AG-270, IDE397) or methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors (e.g., AMG193).
• •Uncontrolled or active central nervous system (CNS) disease, including untreated or symptomatic brain metastases, spinal cord compression, or leptomeningeal carcinomatosis.
• •Active bleeding, history of major bleeding events within the past 6 months, or tumors associated with a high risk of vascular invasion.
• •Receipt of systemic anticancer therapy, radiation therapy, live vaccine, or major surgical procedures within protocol-specified washout periods.
• •Active or uncontrolled infections, including tuberculosis (TB), (COVID-19, known human immunodeficiency virus (HIV) infection, or uncontrolled hepatitis B virus (HBV) infection.
• •Note: Additional eligibility criteria may apply.